Literature DB >> 19949078

Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1.

Nadine C Salisch1, Daniel E Kaufmann, Amany S Awad, R Keith Reeves, Daniel P Tighe, Yuan Li, Michael Piatak, Jeffrey D Lifson, David T Evans, Florencia Pereyra, Gordon J Freeman, R Paul Johnson.   

Abstract

Ongoing antigenic stimulation appears to be an important prerequisite for the persistent expression of programmed death 1 (PD-1), an inhibitory TCR coreceptor of the CD28 family. Although recent publications have emphasized the utility of PD-1 as a marker for dysfunctional T cells in chronic viral infections, its dependence on antigenic stimulation potentially renders it a sensitive indicator of low-level viral replication. To explore the antigenic threshold for the maintenance of PD-1 expression on virus-specific T cells, we compared PD-1 expression on virus-specific and memory T cell populations in controlled and uncontrolled SIV and HIV-1 infection. In both controlled live attenuated SIV infection in rhesus macaques and HIV-1 infection in elite controllers, elevated levels of PD-1 expression were observed on SIV- and HIV-1-specific CD8(+) T cells. However, in contrast to chronic wild-type SIV infection and uncontrolled HIV-1 infection, controlled SIV/HIV-1 infection did not result in increased expression of PD-1 on total memory T cells. PD-1 expression on SIV-specific CD8(+) T cells rapidly decreased after the emergence of CTL escape in cognate epitopes, but was maintained in the setting of low or undetectable levels of plasma viremia in live attenuated SIV-infected macaques. After inoculation of naive macaques with a single-cycle SIV, PD-1 expression on SIV-specific CD8(+) T cells initially increased, but was rapidly downregulated. These results demonstrate that PD-1 can serve as a sensitive indicator of persistent, low-level virus replication and that generalized PD-1 expression on T lymphocytes is a distinguishing characteristic of uncontrolled lentiviral infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19949078      PMCID: PMC2810496          DOI: 10.4049/jimmunol.0902781

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats.

Authors:  M Roederer
Journal:  Cytometry       Date:  2001-11-01

2.  Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?

Authors:  Thorsten U Vogel; Thomas C Friedrich; David H O'Connor; William Rehrauer; Elizabeth J Dodds; Heather Hickman; William Hildebrand; John Sidney; Alessandro Sette; Austin Hughes; Helen Horton; Kathy Vielhuber; Richard Rudersdorf; Ivna P De Souza; Matthew R Reynolds; Todd M Allen; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Development and homeostasis of T cell memory in rhesus macaque.

Authors:  Christine J Pitcher; Shoko I Hagen; Joshua M Walker; Richard Lum; Bridget L Mitchell; Vernon C Maino; Michael K Axthelm; Louis J Picker
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

4.  Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.

Authors:  Dan H Barouch; Jennifer Kunstman; Marcelo J Kuroda; Jörn E Schmitz; Sampa Santra; Fred W Peyerl; Georgia R Krivulka; Kristin Beaudry; Michelle A Lifton; Darci A Gorgone; David C Montefiori; Mark G Lewis; Steven M Wolinsky; Norman L Letvin
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

5.  CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.

Authors:  T M Allen; B R Mothé; J Sidney; P Jing; J L Dzuris; M E Liebl; T U Vogel; D H O'Connor; X Wang; M C Wussow; J A Thomson; J D Altman; D I Watkins; A Sette
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors:  Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

7.  A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.

Authors:  Welkin E Johnson; Jennifer Morgan; Julie Reitter; Bridget A Puffer; Susan Czajak; Robert W Doms; Ronald C Desrosiers
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia.

Authors:  Guido Silvestri; Donald L Sodora; Richard A Koup; Mirko Paiardini; Shawn P O'Neil; Harold M McClure; Silvija I Staprans; Mark B Feinberg
Journal:  Immunity       Date:  2003-03       Impact factor: 31.745

9.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.

Authors:  S Y Tseng; M Otsuji; K Gorski; X Huang; J E Slansky; S I Pai; A Shalabi; T Shin; D M Pardoll; H Tsuchiya
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

View more
  35 in total

1.  Antiretroviral therapy reduces the magnitude and T cell receptor repertoire diversity of HIV-specific T cell responses without changing T cell clonotype dominance.

Authors:  Joseph A Conrad; Ramesh K Ramalingam; Coley B Duncan; Rita M Smith; Jie Wei; Louise Barnett; Brenna C Simons; Shelly L Lorey; Spyros A Kalams
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

2.  Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection.

Authors:  Emily S Ford; Jamieson H Greenwald; Aaron G Richterman; Adam Rupert; Lauren Dutcher; Yunden Badralmaa; Ven Natarajan; Catherine Rehm; Colleen Hadigan; Irini Sereti
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

Review 3.  Animal models for viral infection and cell exhaustion.

Authors:  Colleen S McGary; Guido Silvestri; Mirko Paiardini
Journal:  Curr Opin HIV AIDS       Date:  2014-09       Impact factor: 4.283

4.  Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers.

Authors:  Julia M Shaw; Peter W Hunt; J William Critchfield; Delandy H McConnell; Juan Carlos Garcia; Richard B Pollard; Ma Somsouk; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

5.  Dominant clonotypes within HIV-specific T cell responses are programmed death-1high and CD127low and display reduced variant cross-reactivity.

Authors:  Joseph A Conrad; Ramesh K Ramalingam; Rita M Smith; Louise Barnett; Shelly L Lorey; Jie Wei; Brenna C Simons; Shanmugalakshmi Sadagopal; Dirk Meyer-Olson; Spyros A Kalams
Journal:  J Immunol       Date:  2011-05-11       Impact factor: 5.422

Review 6.  Advances toward Curing HIV-1 Infection in Tissue Reservoirs.

Authors:  Lisa J Henderson; Lauren B Reoma; Joseph A Kovacs; Avindra Nath
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

Review 7.  PD-1 coinhibitory signals: the link between pathogenesis and protection.

Authors:  Deanna A Kulpa; Mariam Lawani; Anthony Cooper; Yoav Peretz; Jeff Ahlers; Rafick-Pierre Sékaly
Journal:  Semin Immunol       Date:  2013-03-31       Impact factor: 11.130

8.  Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Alison E Hogg; Thorsten Demberg; Katherine McKinnon; David Venzon; Egidio Brocca-Cofano; Janet Dipasquale; Eun M Lee; Lauren Hudacik; Ranajit Pal; Yongjun Sui; Jay A Berzofsky; Linda Liu; Solomon Langermann; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-10-09       Impact factor: 3.616

9.  Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage.

Authors:  Thomas C Greenough; Shalyn C Campellone; Robin Brody; Surbhi Jain; Victor Sanchez-Merino; Mohan Somasundaran; Katherine Luzuriaga
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

10.  A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.

Authors:  Panagiotis Vagenas; Meropi Aravantinou; Vennansha G Williams; Edith Jasny; Michael Piatak; Jeffrey D Lifson; Andres M Salazar; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.